glp-1 patch fda approved issued 25 warning letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of glp-1 patches efficacy Do Really

Goel et al

doi: 10.1007/s10620-025-08964-6 104 AndersonSRAyoubMCoatsSMcHenrySTanTDeepakP

There is no TGA-registered BPC-157 product for therapeutic use in Australia, and as of June 2024 BPC-157 is a Schedule 4 (prescription-only) substance, meaning any legal supply must come through a doctors prescription via a compounding pharmacy

Both SubQ and IM routes appear in clinic and community protocols, while IV administration is also common in supervised settings

Common reconstitution approaches create concentrations enabling convenient dose measurement with insulin syringes

A GHK-Cu solution that remains clear after reconstitution is a signal worth investigating before proceeding